Frances A. Collichio

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer et al. · Clinical Cancer Research · 2007 · 2.1K citations · Full text

Medicine, Oncology, Breast Oncology +14

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney, Igor Puzanov, Frances A. Collichio et al. · Journal of Clinical Oncology · 2017 · 617 citations

Medicine, Oncology, Pharmacotherapy +17

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder et al. · Journal of Clinical Oncology · 2013 · 595 citations · Full text

Medicine, Dermatology, Oncology +17

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Robert H.I. Andtbacka, Frances A. Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · 438 citations · Full text

Medicine, Immunology, Oncology +17